Bio-Rad Laboratories (BIO-B) Payables (2009 - 2026)

Bio-Rad Laboratories (BIO-B) has 18 years of Payables data on file, last reported at $533.6 million in Q1 2026.

• Payables for Q1 2026 came in at $533.6 million, up 283.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $533.6 million (up 283.61% YoY), and the FY2025 annual result was $130.3 million, up 5.51% from the prior year.
• Payables grew to $533.6 million in Q1 2026 per BIO-B's latest filing, from $130.3 million in the prior quarter.
• Over five years, Payables peaked at $533.6 million in Q1 2026 and troughed at $103.2 million in Q1 2024.
• A 5-year average of $159.9 million and a median of $139.1 million in 2025 frame the typical range for Payables.
• The sharpest annual moves came in 2024 and 2026: Payables slumped 36.08% in 2024, then soared 283.61% in 2026.
• A 5-year view of Payables shows it stood at $135.5 million in 2022, then gained by 7.08% to $145.1 million in 2023, then retreated by 14.89% to $123.5 million in 2024, then gained by 5.51% to $130.3 million in 2025, then surged by 309.52% to $533.6 million in 2026.
• Business Quant data shows BIO-B's Payables at $533.6 million in Q1 2026, $130.3 million in Q4 2025, and $130.1 million in Q3 2025.